Mental & Emotional Health

FDA Wants Stronger Warnings on Sleep Disorder Drugs
Drugs Can Cause “Sleep Driving” Incidents

The U.S. Food and Drug Administration wants tougher language on drugs for sleep disorders, beefing up the warnings to consumers about potential risks. The sedative-hypnotic drug products - a class of drugs used to induce and maintain sleep - carry risks of severe allergic reactions and complex sleep-related behaviors, which may include sleep-driving, the agency said.

Sleep driving is defined as driving while not fully awake after ingestion of a sedative-hypnotic product, with no memory of the event. A year ago Rep. Patrick Kennedy (D-RI) was involved in a highly publicized mishap, crashing his car into a barricade at the U.S. Capitol. He was taking the sleep disorder drug Ambien at the time. My question is, why would you DRIVE after you’ve taken a sleeping pill!?!?

“There are a number of prescription sleep aids available that are well-tolerated and effective for many people,” said Steven Galson, M.D., MPH, director of FDA�s Center for Drug Evaluation and Research. “However, after reviewing the available post-marketing adverse event information for these products, FDA concluded that labeling changes are necessary to inform health care providers and consumers about risks.”

In December 2006, FDA sent letters to manufacturers of products approved for the treatment of sleep disorders requesting that the whole class of drugs revise product labeling to include warnings about the following potential adverse events:
• Anaphylaxis (severe allergic reaction) and angioedema (severe facial swelling), which can occur as early as the first time the product is taken.
• Complex sleep-related behaviors which may include sleep-driving, making phone calls, and preparing and eating food (while asleep). On Ambien I had a conversation with the bathtub once … that stuff is not for me!

FDA said it has been working with the product manufacturers over the past three months to update labeling, notify health care providers and inform consumers of these risks. The guides will contain FDA-approved information such as proper use and the recommendation to avoid ingesting alcohol and/or other central nervous system depressants. Although all sedative-hypnotic products have these risks, the agency said there may be differences among products in how often they occur. For this reason, FDA has recommended that the drug manufacturers conduct clinical studies to investigate the frequency with which sleep-driving and other complex behaviors occur in association with individual drug products.

The medications that are the focus of the revised labeling include the following 13 products:
Ambien/Ambien CR (Sanofi Aventis)
Butisol Sodium (Medpointe Pharm HLC)
Carbrital (Parke-Davis)
Dalmane (Valeant Pharm)
Doral (Questcor Pharms)
Halcion (Pharmacia & Upjohn)
Lunesta (Sepracor)
Placidyl (Abbott)
Prosom (Abbott)
Restoril (Tyco Healthcare)
Rozerem (Takeda)
Seconal (Lilly)
Sonata (King Pharmaceuticals)

sleeping aids, sleep-driving, sleep-walking, FDA, Ambien, Ambien CR, Butisol Sodium, Carbrital, Dalmane, Doral, Halcion, Lunesta, Placidyl, Prosom, Restoril, Rozerem, Seconal, Sonata